https://www.thebostonexaminer.com/article/912767525-treeline-inc-named-by-forbes-2026-as-america-s-best-recruiting-staffing-firms The Boston Examiner en PressRelease 2026-05-16T12:45:50+00:00 Treeline Inc. Named by Forbes 2026 as America’s Best Recruiting & Staffing Firms https://d2c0db5b8fb27c1c9887-9b32efc83a6b298bb22e7a1df0837426.ssl.cf2.rackcdn.com/24856685-treeline-inc-named-one-of-amer-2752x1536.png https://www.thebostonexaminer.com/article/912934001-walker-s-gymnastics-dance-captures-massachusetts-state-championship-signaling-new-era-of-growth-in-lowell The Boston Examiner en PressRelease 2026-05-15T23:02:07+00:00 Walker’s Gymnastics & Dance Captures Massachusetts State Championship, Signaling New Era of Growth in Lowell https://d2c0db5b8fb27c1c9887-9b32efc83a6b298bb22e7a1df0837426.ssl.cf2.rackcdn.com/24858378-coach-carlos-1163x641.jpeg https://www.thebostonexaminer.com/article/912827325-oxeia-biopharmaceuticals-named-most-innovative-mtbi-company-2026 The Boston Examiner en PressRelease 2026-05-15T14:00:00+00:00 OXEIA BIOPHARMACEUTICALS NAMED MOST INNOVATIVE mTBI COMPANY 2026 https://www.thebostonexaminer.com/article/912905115-vibesies-launches-ai-native-hosting-platform-built-around-vibe-coding The Boston Examiner en PressRelease 2026-05-15T13:00:00+00:00 Vibesies Launches AI-Native Hosting Platform Built Around Vibe Coding https://d2c0db5b8fb27c1c9887-9b32efc83a6b298bb22e7a1df0837426.ssl.cf2.rackcdn.com/24857513-vibesies-com-hp-15-202605150016-2400x1350.png https://www.thebostonexaminer.com/article/913091483-korro-bio-reports-inducement-grant-under-nasdaq-listing-rule-5635-c-4 The Boston Examiner en PressRelease 2026-05-15T20:05:00+00:00 Korro Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) https://ml.globenewswire.com/media/d49fc3c4-5cf6-4b89-8434-2eadfff25c26/small/korro-logo-rgb-jpg.jpg https://www.thebostonexaminer.com/article/913091515-candel-therapeutics-reports-extended-clinical-benefit-over-multiple-clinical-endpoints-in-patients-from-phase-3-trial-of-aglatimagene-besadenovec The Boston Examiner en PressRelease 2026-05-15T20:05:00+00:00 Candel Therapeutics Reports Extended Clinical Benefit Over Multiple Clinical Endpoints in Patients from Phase 3 Trial of Aglatimagene Besadenovec (CAN-2409) in Localized Prostate Cancer Under Prolonged Follow-up at AUA 2026 Annual Meeting https://ml.globenewswire.com/media/8b82e1e3-4a67-4472-a7c8-05f9d24c9bb0/small/candel-logo-fullcolor-4-png.png https://www.thebostonexaminer.com/article/913091481-acrivon-therapeutics-announces-inducement-grant-under-nasdaq-listing-rule-5635-c-4 The Boston Examiner en PressRelease 2026-05-15T20:00:00+00:00 Acrivon Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) https://ml.globenewswire.com/media/7935747b-f8f5-48e8-b925-6935300d63e5/small/acrivon-logo-jpg.jpg https://www.thebostonexaminer.com/article/908369038-aifchem-enhances-drug-discovery-as-a-reliable-innovative-chiral-building-blocks-solution-provider The Boston Examiner en PressRelease 2026-05-15T05:18:53+00:00 AiFChem Enhances Drug Discovery as a Reliable Innovative Chiral Building Blocks Solution Provider https://d2c0db5b8fb27c1c9887-9b32efc83a6b298bb22e7a1df0837426.ssl.cf2.rackcdn.com/24841277-reliable-innovative-chiral-buil-968x733.png https://www.thebostonexaminer.com/article/913020523-microbot-medical-to-hold-analysts-and-investors-conference-call-to-review-recent-progress-executive-team-will-be-joined-by-current-users-of-the The Boston Examiner en PressRelease 2026-05-15T13:56:07+00:00 Microbot Medical to Hold Analysts and Investors Conference Call to Review Recent Progress; Executive Team will be Joined by Current Users of the LIBERTY Endovascular Robotic System, Dr. Charles Briggs and Dr. Zachary Bercu https://ml.globenewswire.com/media/346df7fb-c134-40c2-970a-39bcbaf974cd/small/mbot-logo-rgb-jpg.jpg https://www.thebostonexaminer.com/article/913020465-ai-and-advanced-diagnostics-transform-cancer-detection-market-amid-rising-healthcare-investment The Boston Examiner en PressRelease 2026-05-15T13:49:09+00:00 AI and Advanced Diagnostics Transform Cancer Detection Market Amid Rising Healthcare Investment https://ml.globenewswire.com/media/d0c282b6-d496-45a8-a941-33fa5c3e824c/small/bcc-logo-1200-630-png.png https://www.thebostonexaminer.com/article/913020272-flywire-continues-execution-on-buyback-plan-through-direct-repurchase-agreement The Boston Examiner en PressRelease 2026-05-15T13:00:00+00:00 Flywire Continues Execution on Buyback Plan Through Direct Repurchase Agreement https://ml.globenewswire.com/media/9b1123f3-5f90-4036-ab7b-c4c3d1f5491b/small/flywire-logo-jpg.jpg https://www.thebostonexaminer.com/article/913003419-lifeward-reports-first-quarter-2026-financial-results The Boston Examiner en PressRelease 2026-05-15T12:00:00+00:00 Lifeward Reports First Quarter 2026 Financial Results https://ml.globenewswire.com/media/9343d7ac-5bc7-4a60-a2c9-a41bf7b5e007/small/lifeward-full-logo-rgb-for-web-01-jpg.jpg https://www.thebostonexaminer.com/article/913003429-electra-ai-and-iron-horse-acquisition-ii-corp-nasdaq-irho-announce-filing-of-registration-statement-on-form-s-4-with-the-sec-in-connection-with The Boston Examiner en PressRelease 2026-05-15T12:00:00+00:00 ELECTRA AI and Iron Horse Acquisition II Corp. (Nasdaq: IRHO) Announce Filing of Registration Statement on Form S-4 with the SEC in Connection with their Proposed Business Combination https://ml.globenewswire.com/media/NWU0NmI5NDUtM2FhYS00N2I4LTlhYzItMjgxMThjMmI2M2VmLTEzMjI5MjctMjAyNi0wNS0xNS1lbg==/tiny/ELECTRA-AI.png https://www.thebostonexaminer.com/article/913003157-immuneering-reports-first-quarter-2026-financial-results-and-provides-business-updates The Boston Examiner en PressRelease 2026-05-15T11:35:00+00:00 Immuneering Reports First Quarter 2026 Financial Results and Provides Business Updates https://ml.globenewswire.com/media/81d0c83f-ae53-4d6e-9c5e-d6963e02f29d/small/immuneering-logo-cropped-1-jpg.jpg https://www.thebostonexaminer.com/article/913003147-kymera-therapeutics-announces-presentations-on-kt-621-a-first-in-class-oral-stat6-degrader-at-the-society-for-investigative-dermatology-and The Boston Examiner en PressRelease 2026-05-15T11:00:00+00:00 Kymera Therapeutics Announces Presentations on KT-621, a First-In-Class, Oral STAT6 Degrader, at the Society for Investigative Dermatology and American Thoracic Society Congresses https://ml.globenewswire.com/media/4d3d3283-c57d-401e-9e1b-53f17e22d76b/small/kymera-logo-rgb-denim-marigold-high-res-png.png https://www.thebostonexaminer.com/article/913003191-ocular-therapeutix-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4 The Boston Examiner en PressRelease 2026-05-15T11:00:00+00:00 Ocular Therapeutix™ Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) https://ml.globenewswire.com/media/20ee0f50-7288-4f81-8546-f2ad2050ddbf/small/ocul-logo-jpg.jpg